Skip to search formSkip to main contentSkip to account menu

NSC 95580

Known as: NSC-95580 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

hexamethylene bisacetamide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1991
1991
Phase I bioavailability and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered via nasogastric tube.
A Phase I clinical trial and pharmacological study of nasogastrically administered hexamethylene bisacetamide, a polar-planar… 
1989
1989
Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).
Hexamethylene bisacetamide (HMBA), a potent differentiating agent, was administered to patients with refractory malignant tumors… 
Highly Cited
1987
Highly Cited
1987
Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
Hexamethylene bisacetamide (HMBA), a potent differentiating agent, was tested in patients with refractory, solid tumors. Twenty… 
1987
1987
Prolonged infusion of hexamethylene bisacetamide: a phase I and pharmacological study.
Hexamethylene bisacetamide (HMBA, NSC 95580), a potent polar-planar differentiating agent in vitro, was studied in a phase I… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)